Amplitude Venture Capital Launches CAD $200 Million Fund
Amplitude Venture Capital today announced the launch of a CAD $200 million fund to continue its successful investment strategy of building globally competitive Canadian healthcare companies. The Fund is focused on developing platform companies based on outstanding Canadian precision medicine innovation.
OBIO’s “Project Management Essentials for Every Health Science Entrepreneur” Event in Review
On October 24th, OBIO hosted “Project Management Essentials for Every Health Science Entrepreneur” led by Ashwini Bhaskar who shared from his 20 years of experience. The purpose of the workshop was to introduce basic project knowledge and common terminology, to provide insights into where to go for more information and provide some simple take-aways that could be used immediately.
Synaptive Announces Co-Marketing Collaboration with Stryker, Expansion Into Spine Market
Synaptive Medical, a leader in automation and robotics, announced today a strategic commercial expansion into the spinal surgery market. As part of this expansion, Synaptive is also announcing a co-marketing collaboration with Stryker’s Advanced Guidance Technologies business for the company’s robotically controlled digital microscope, Modus V™.
RetiSpec Receives Award from Alzheimer's Drug Discovery Foundation (ADDF)
RetiSpec Inc. announced that it has received an award of up to USD $500,000, which includes a direct investment in the company, from the Alzheimer's Drug Discovery Foundation to fund the accelerated development of retinal imaging technology for the early detection of Alzheimer's disease.
NERv Announces $1M CAD in Pre-Seed Round
NERv Technology Inc., an innovative medtech venture co-founded by a number of University of Waterloo alumni, has secured $1 million CAD in pre-seed funding.
Iris Technologies acquired by Accelera Medtech Canada
Iris Technologies announced this week that Accelera Medtech Canada had acquired the company and its flagship product - the Iris Monitor - the world's first computer monitors clinically proven to help concussion patients reduce the painful symptoms of light sensitivity when using a computer.
KA Imaging announced as one of 10 companies in this year’s Lazaridis ScaleUp Program
The Lazaridis Institute for the Management of Technology Enterprises has selected 10 of the country’s most promising technology companies to participate in the fifth cohort of the Lazaridis ScaleUp Program. The institute, housed in Wilfrid Laurier University’s Lazaridis School of Business and Economics, supports Canada’s tech sector through research and programming focused on growth and innovation. Its ScaleUp Program helps companies grow globally through mentorship, programming, and access to a global network of experts.
Apply for Canadian Mission to Arab Health Conference in Dubai
With funding support from Global Affairs Canada, Medtech Canada is inviting Candian medtech companies to apply to receive financial support to attend Arab Health in Dubai, Jan 27-30, 2020.
AmacaThera Closes US$3.6M Seed Financing Round
AmacaThera Inc. is pleased to announce the closing of its US$3.6M seed financing round. A first close of the round was led by Sprout BioVentures/ Viva Biotech with participation from Grey Sky Venture Partners, and the round was recently completed with an investment by Toronto-based Lumira Ventures.
RetiSpec Technology Featured in Globe and Mail
This week, the Globe & Mail reported how RetiSpec's retinal scan has the potential to detect patterns specific to Alzheimer's disease even before symptoms develop using a specialized camera and software that analyzes how light reflects off the back of a person's eye.
Reviewing OBIO's Primary Market Research Workshop
Last week OBIO hosted Gary Svoboda (CEO, Adventus Research + Consulting) who provided the audience practical steps they can use to validate technology with primary market research.
OBIO at MedTech Conference in Boston
This year's AdvaMed MedTech Conference in Boston was a fantastic event. OBIO was in attendance for meetings and conversations with US and global investors and strategics about what's coming up for the health science industry in Canada. There was tons of enthusiasm and interest to capitalize on as we head into 2020.
Recap: OBIO CAAP Alumni Group Dinner
On September 17th, OBIO held a dinner to bring together CAAP and CAAP Alumni companies. OBIO would like to thank everyone who came out and joined us to discuss common experiences, challenges and what's coming next.
Reviewing OBIO at RESI Boston
On September 10th, OBIO organized a cross-border networking event in Boston at the Consulate General of Canada. The event was supported by the Consulate General and law firms Fasken and Choate. Over 45 investors, strategics, as well as executives from high potential Canadian health science companies packed the Canada Room at the Consulate and resulted in numerous investor-company interactions.
Apply for the Genomic Applications Partnership Program (GAPP)
Ontario Genomics is pleased to announce that a new round of Genome Canada’s Genomic Applications Partnership Program (GAPP) is now open (Round 18). The program provides a unique opportunity for Receptor organizations to collaborate with an ’omics researcher, and to leverage their R&D investments with public funding.
Application deadline: October 28, 2019
Interface Biologics Announces Sale of Surface Modification Business to Evonik
Interface Biologics Inc. (“IBI”), a privately held, commercial stage developer of innovative material science technologies for Medtech and Pharmaceutical applications, is pleased to announce the sale of its surface modification business to Evonik, a German based specialty chemical company with revenues in excess of €13 billion in 2018.
Venture capital has strongest first half on record, with $2.15-billion raised
This week, the Globe & Mail reported that venture-capital investment surged to its strongest first half on record, injecting $2.15-billion into Canadian startups and scale-ups, according to the Canadian Venture Capital & Private Equity Association (CVCA).
FedDev Ontario announces $6.24 million investment in OBIO
FedDev Ontario is investing up to $6.24 million for the Ontario Bioscience Innovation Organization (OBIO®) to boost investment, market access and mentorship opportunities for companies across southern Ontario looking to commercialize their medical innovations.
iMerciv Accepted into CTA Silicon Valley Fall 2019 Cohort
iMerciv was accepted into the Fall 2019 Cohort of the Canadian Technology Accelerator in Silicon Valley, which helps high-potential Canadian technology companies access the unique resources of Silicon Valley to grow at a global scale.
Profound Medical Announces U.S. FDA 510(k) Clearance for TULSA-PRO®
Profound Medical announced that they have received 510(k) clearance from the U.S. Food and Drug Administration to market TULSA-PRO® for ablation of prostate tissue.